Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.

Haemophilia : the official journal of the World Federation of Hemophilia·1999

Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.

Thrombosis and haemostasis·1996

Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.

Blood·1994

Medical management of extensive spinal epidural hematoma in a child with factor IX deficiency.

Pediatric emergency care·1994

Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage.

The American journal of pediatric hematology/oncology·1993

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

The New England journal of medicine·1993

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

Seminars in hematology·2026

The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting.

Seminars in hematology·2026

Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis.

Seminars in hematology·2026

Germline predisposition in myeloproliferative neoplasms.

Seminars in hematology·2026

Alloimmunization in sickle cell disease: Addressing an ongoing clinical challenge.

Seminars in hematology·2026

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026

CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.

Annals of gastroenterological surgery·2026

Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.

Open forum infectious diseases·2026

Prevalence of neutralizing autoantibodies against type I interferon in dengue patients.

Journal of human immunity·2026

Spatial niche remodeling of senescent liver-resident immune cells and its role in chronic liver diseases.

Frontiers in medicine·2026

IL1RAP Is Associated With an Inflammation-Immunity-Related State in Skin Cutaneous Melanoma: Integrative Evidence From Pan-Cancer Data and Melanoma Immunotherapy Cohorts.

International journal of genomics·2026

Mitochondrial checkpoint for interferon responses in macrophages.

Exploration of targeted anti-tumor therapy·2026

Related Experiment Videos

Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group

Related Concept Videos

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.

Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.

Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.

Medical management of extensive spinal epidural hematoma in a child with factor IX deficiency.

Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage.

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review.

The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting.

Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis.

Germline predisposition in myeloproliferative neoplasms.

Alloimmunization in sickle cell disease: Addressing an ongoing clinical challenge.

Pain in SCD-Many mechanisms and mysteries.

CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.

Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.

Prevalence of neutralizing autoantibodies against type I interferon in dengue patients.

Spatial niche remodeling of senescent liver-resident immune cells and its role in chronic liver diseases.

IL1RAP Is Associated With an Inflammation-Immunity-Related State in Skin Cutaneous Melanoma: Integrative Evidence From Pan-Cancer Data and Melanoma Immunotherapy Cohorts.

Mitochondrial checkpoint for interferon responses in macrophages.

Related Experiment Videos

Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group

Related Concept Videos

Related Articles